Gilead Sciences (GILD)
(Delayed Data from NSDQ)
$83.61 USD
+0.57 (0.69%)
Updated Sep 27, 2024 04:00 PM ET
After-Market: $83.61 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$83.61 USD
+0.57 (0.69%)
Updated Sep 27, 2024 04:00 PM ET
After-Market: $83.61 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth A Momentum A VGM
Zacks News
Ligand (LGND) Proposes to Buy U.K.'s Drug Discovery Biotech
by Zacks Equity Research
Ligand (LGND) makes an offer to acquire U.K.-based drug discovery biotech Vernalis to drive the same platform in its portfolio.
Alnylam (ALNY) Gets FDA Nod for First-Ever RNAi Therapeutic
by Zacks Equity Research
Alnylam (ALNY) receives FDA approval for Onpattro to treat polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults.
Amicus (FOLD) Gets FDA Nod for Fabry Disease Drug Galafold
by Zacks Equity Research
Amicus (FOLD) gets a major boost with the FDA approval of lead candidate, Galafold (migalastat) 123 mg capsules for the treatment of Fabry disease.
Biotech ETFs in Focus on String of Q2 Earnings Beat
by Sanghamitra Saha
Biotech ETFs draw attention post impressive Q2 results.
Puma Biotech (PBYI) Q2 Loss Narrows, Nerlynx Drives Sales
by Zacks Equity Research
Puma Biotech (PBYI) posts narrower-than-estimated loss in Q2. Also, rapid growth of its only marketed drug, Nerlynx, boosts sales.
Agenus' (AGEN) Q2 Loss Narrower Than Expected, Revenues Beat
by Zacks Equity Research
Agenus (AGEN) posts narrower-than-expected loss in the second quarter of 2018 and expects to file three investigational new drugs by the end of 2018.
Keryx's (KERX) Loss Wider Than Expected in Q2, Sales Lag
by Zacks Equity Research
Keryx (KERX) posts wider-than-expected loss in Q2. Moreover, revenues miss the mark.
PDL BioPharma (PDLI) Q2 Earnings Top, Revenues Slump Y/Y
by Zacks Equity Research
PDL BioPharma's (PDLI) earnings trump estimates in Q2. Lower royalties and license fees cause a significant decline in year-over-year revenues.
Aerie (AERI) Earnings Miss in Q2, Rhopressa Performs Well
by Zacks Equity Research
Aerie's (AERI) Q2 loss is wider than expected on account of higher expenses. Nevertheless, Rhopressa's sales beat estimates as demand picks up.
Horizon Pharma (HZNP) Q2 Earnings & Sales Beat, Shares Rise
by Zacks Equity Research
Horizon Pharma (HZNP) beat earnings and sales estimates in the second quarter of 2018.
Novo Nordisk (NVO) Beats Q2 Earnings and Sales Estimates
by Zacks Equity Research
Novo Nordisk (NVO) beats earnings and sales estimates in the second quarter of 2018. Majority of sales growth originated from drugs like Victoza , Ozempic , Xultophy and Saxenda.
Inovio (INO) Q2 Loss Narrows, Revenues Surpass Estimates
by Zacks Equity Research
Inovio's (INO) Q2 loss betters estimates. Also, the company rides high on revenue beat.
AVEO Pharmaceuticals (AVEO) Q2 Loss In Line, Revenues Miss
by Zacks Equity Research
AVEO Pharmaceuticals' (AVEO) loss in the second quarter meets estimates while revenues miss the same.
Merrimack (MACK) Suffers Wider-Than-Expected Loss in Q2
by Zacks Equity Research
Merrimack's (MACK) loss is wider than expected in Q2 but narrower than the year-ago quarter's deficit. Meanwhile, the company did not generate any revenues in the reported quarter.
VIVUS (VVUS) Q2 Loss Wider Than Expected, Revenues Up Y/Y
by Zacks Equity Research
VIVUS (VVUS) reports wider-than-expected loss in the second quarter. However, sales increased year over year.
Prothena (PRTA) Q2 Earnings Lag Estimates, Pipeline in Focus
by Zacks Equity Research
Prothena (PRTA) posts wider-than-expected loss in the second quarter. With the failure of lead drug, NEOD001, the focus is now mainly on its mid-stage candidate, prasinezumab.
Biotech Stock Roundup: Regeneron Shines, BLUE Surges, ONCE Plunges
by Zacks Equity Research
The last leg of Q2 earnings in the biotech sector saw Regeneron firing all cylinders. The company also collaborated with bluebird bio, which impressed investors.
Radius (RDUS) Q2 Loss Narrower Than Expected, Tymlos Sales Up
by Zacks Equity Research
Radius' (RDUS) Q2 results are encouraging as sales of its lead osteoporosis drug, Tymlos, continue to gain traction.
Alnylam's (ALNY) Q2 Loss Wider Than Expected, Sales Beat
by Zacks Equity Research
Alnylam (ALNY) posted wider-than-expected loss in the second quarter of 2018 and received a positive opinion from the CHMP for the marketing authorization of patisiran.
Q2 Scorecard & Research Reports for Gilead, American Tower & Others
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Gilead (GILD), American Tower (AMT) and Chubb (CB).
Ultragenyx (RARE) Posts Narrower-than-Expected Loss in Q2
by Zacks Equity Research
Ultragenyx posts narrower than expected loss and revenues beat estimates in the second quarter of 2018.
Epizyme (EPZM) Q2 Loss Narrows, Shares Crash 24% on Setbacks
by Zacks Equity Research
Shares of Epizyme (EPZM) crashed almost 24% following the second quarter earnings release. The company delayed the first ever new drug application filing of its pipeline candidate-tazemetostat by six months.
bluebird (BLUE) Q2 Loss Wider Than Expected, Revenues Miss
by Zacks Equity Research
bluebird (BLUE) incurs Q2 loss on account of higher expenses and lower revenues. Nevertheless, the pipeline progress looks encouraging.
Acorda (ACOR) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Acorda Therapeutics (ACOR) rides high on earnings as well as revenue beat in Q2.
Intercept (ICPT) Gains on Solid Q2 Results, Ocaliva Recovers
by Zacks Equity Research
Intercept (ICPT) gains on a better-than-expected second quarter as loss narrows and sales surpass estimates on a significant recovery in Ocaliva.